Sectors & Industries HealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2026)
Top general drug manufacturer stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +28.50% per year, and are the best general drug manufacturer stocks to buy now. Learn More.

Industry: Drug Manufacturers - Gene...

Price Value Growth Financials Momentum Sentiment Forecast Dividends Due Diligence

General Drug Manufacturers is Zen Rated A and is the 8th ranked industry out of 145 stock market industries

Ticker	Company	Zen Rating	Value	Growth	Momentum	Sentiment	Safety	Financials	AI	1w Zen Rating	1m Zen Rating	3m Zen Rating	1y Zen Rating
BMY	BRISTOL MYERS SQUIBB CO	A	A	C	C	C	B	B	B	A	A	A	B
GSK	GSK PLC	B	A	C	C	B	B	C	B	B	B	B	B
GILD	GILEAD SCIENCES INC	B	B	D	C	B	A	B	B	B	C	A	B
ABBV	ABBVIE INC	B	C	C	C	C	A	B	C	B	B	B	B
JNJ	JOHNSON & JOHNSON	B	C	C	C	B	B	B	B	B	C	C	B

Upgrade to Premium to View More

Use the proven Zen Ratings quant model to find stocks with high potential to beat the market. Stocks Zen-Rated "A" have beaten the market by +28.50% annually. Learn More

Already have access to Premium?

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in Jul 2026?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best general drug manufacturer stocks to buy right now are:

1. Bristol Myers Squibb Co (NYSE:BMY)

Bristol Myers Squibb Co (NYSE:BMY) is the #1 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Bristol Myers Squibb Co (NYSE:BMY) is: Value: A, Growth: C, Momentum: C, Sentiment: C, Safety: B, Financials: B, and AI: B.

Bristol Myers Squibb Co (NYSE:BMY) has a Due Diligence Score of 50, which is 13 points higher than the general drug manufacturer industry average of 37.

BMY passed 17 out of 38 due diligence checks and has strong fundamentals. Bristol Myers Squibb Co has seen its stock return 26.87% over the past year, underperforming other general drug manufacturer stocks by -9 percentage points.

Bristol Myers Squibb Co has an average 1 year price target of $64.82, an upside of 4.39% from Bristol Myers Squibb Co's current stock price of $62.09.

Bristol Myers Squibb Co stock has a consensus Buy recommendation according to Wall Street analysts. Of the 11 analysts covering Bristol Myers Squibb Co, 45.45% have issued a Strong Buy rating, 0% have issued a Buy, 54.55% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Gsk (NYSE:GSK)

Gsk (NYSE:GSK) is the #2 top general drug manufacturer stock out of 20 with a Zen Rating of B. Stocks with a rating of B have had an average return of +17.17% per year. Learn more.

The Component Grade breakdown for Gsk (NYSE:GSK) is: Value: A, Growth: C, Momentum: C, Sentiment: B, Safety: B, Financials: C, and AI: B.

Gsk (NYSE:GSK) has a Due Diligence Score of 34, which is -3 points lower than the general drug manufacturer industry average of 37. Although this number is below the industry average, our proven quant model rates GSK as a "B".

GSK passed 12 out of 38 due diligence checks and has average fundamentals. Gsk has seen its stock return 34.32% over the past year, underperforming other general drug manufacturer stocks by -2 percentage points.

3. Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) is the #3 top general drug manufacturer stock out of 20 with a Zen Rating of B. Stocks with a rating of B have had an average return of +17.17% per year. Learn more.

The Component Grade breakdown for Gilead Sciences (NASDAQ:GILD) is: Value: B, Growth: D, Momentum: C, Sentiment: B, Safety: A, Financials: B, and AI: B.

Gilead Sciences (NASDAQ:GILD) has a Due Diligence Score of 61, which is 24 points higher than the general drug manufacturer industry average of 37.

GILD passed 22 out of 38 due diligence checks and has strong fundamentals. Gilead Sciences has seen its stock return 14.23% over the past year, underperforming other general drug manufacturer stocks by -22 percentage points.

Gilead Sciences has an average 1 year price target of $157.93, an upside of 22.13% from Gilead Sciences's current stock price of $129.31.

Gilead Sciences stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 14 analysts covering Gilead Sciences, 64.29% have issued a Strong Buy rating, 14.29% have issued a Buy, 21.43% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the general drug manufacturer stocks with highest dividends?

Out of 14 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) has an annual dividend yield of 7.01%, which is 4 percentage points higher than the general drug manufacturer industry average of 2.93%. Pfizer's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Pfizer's dividend has shown consistent growth over the last 10 years.

Pfizer's dividend payout ratio of 131.3% indicates that its high dividend yield might not be sustainable for the long-term.

2. Sanofi (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) has an annual dividend yield of 4.08%, which is 1 percentage points higher than the general drug manufacturer industry average of 2.93%. Sanofi's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Sanofi's dividend has shown consistent growth over the last 10 years.

Sanofi's dividend payout ratio of 58.1% indicates that its high dividend yield is sustainable for the long-term.

3. Bristol Myers Squibb Co (NYSE:BMY)

Bristol Myers Squibb Co (NYSE:BMY) has an annual dividend yield of 4.04%, which is 1 percentage points higher than the general drug manufacturer industry average of 2.93%. Bristol Myers Squibb Co's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Bristol Myers Squibb Co's dividend has shown consistent growth over the last 10 years.

Bristol Myers Squibb Co's dividend payout ratio of 70% indicates that its high dividend yield is sustainable for the long-term.

Why are general drug manufacturer stocks up?

General drug manufacturer stocks were up 0.71% in the last day, and up 1.16% over the last week.

We couldn't find a catalyst for why general drug manufacturer stocks are up.

What are the most undervalued general drug manufacturer stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued general drug manufacturer stocks right now are:

1. Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) is the most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Biogen has a valuation score of 71, which is 40 points higher than the general drug manufacturer industry average of 31. It passed 5 out of 7 valuation due diligence checks.

Biogen's stock has gained 52.49% in the past year. It has overperformed other stocks in the general drug manufacturer industry by 16 percentage points.

2. Bristol Myers Squibb Co (NYSE:BMY)

Bristol Myers Squibb Co (NYSE:BMY) is the second most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Bristol Myers Squibb Co has a valuation score of 29, which is -2 points higher than the general drug manufacturer industry average of 31. It passed 2 out of 7 valuation due diligence checks. Although this number is below the industry average, our proven quant model rates BMY a Valuation Rating of "A".

Bristol Myers Squibb Co's stock has gained 26.87% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -9 percentage points.

3. Gsk (NYSE:GSK)

Gsk (NYSE:GSK) is the third most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Gsk has a valuation score of 43, which is 12 points higher than the general drug manufacturer industry average of 31. It passed 3 out of 7 valuation due diligence checks.

Gsk's stock has gained 34.32% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -2 percentage points.

Are general drug manufacturer stocks a good buy now?

53.85% of general drug manufacturer stocks rated by analysts are a buy right now. On average, analysts expect general drug manufacturer stocks to rise by 8.17% over the next year.

6.25% of general drug manufacturer stocks have a Zen Rating of A (Strong Buy), 43.75% of general drug manufacturer stocks are rated B (Buy), 43.75% are rated C (Hold), 6.25% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 41.99x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.